Targeted therapies: cui prodest?
- PMID: 17925568
- DOI: 10.1200/JCO.2007.12.7613
Targeted therapies: cui prodest?
Comment on
-
Targeted therapy trials: approval strategies, target validation, or helping patients?J Clin Oncol. 2007 May 1;25(13):1639-41. doi: 10.1200/JCO.2006.09.8384. J Clin Oncol. 2007. PMID: 17470854 No abstract available.
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.J Clin Oncol. 2007 May 1;25(13):1658-64. doi: 10.1200/JCO.2006.08.1620. J Clin Oncol. 2007. PMID: 17470858 Clinical Trial.
Similar articles
-
Targeted therapy trials: approval strategies, target validation, or helping patients?J Clin Oncol. 2007 May 1;25(13):1639-41. doi: 10.1200/JCO.2006.09.8384. J Clin Oncol. 2007. PMID: 17470854 No abstract available.
-
Vision and will: the future of the FDA.Oncologist. 2009 Apr;14(4):317-9. doi: 10.1634/theoncologist.2009-0053. Epub 2009 Apr 13. Oncologist. 2009. PMID: 19365098 No abstract available.
-
Monoclonal antibody successes in the clinic.Nat Biotechnol. 2005 Sep;23(9):1073-8. doi: 10.1038/nbt0905-1073. Nat Biotechnol. 2005. PMID: 16151394
-
Phase 0 clinical studies in oncology.Clin Pharmacol Ther. 2009 Feb;85(2):204-7. doi: 10.1038/clpt.2008.246. Epub 2008 Dec 24. Clin Pharmacol Ther. 2009. PMID: 19109589 Review. No abstract available.
-
Targeted and tailored therapy in hemato-oncology: vision for the 21st century.Isr Med Assoc J. 2006 Dec;8(12):843-4. Isr Med Assoc J. 2006. PMID: 17214100 Review.
Cited by
-
Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors.Oncotarget. 2019 Apr 23;10(30):2869-2886. doi: 10.18632/oncotarget.26880. eCollection 2019 Apr 23. Oncotarget. 2019. PMID: 31080558 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical